Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the...
WHO introduces human genome editing global registry
The World Health Organisation has approved the first phase of a new global registry to record the research conducted on human genome editing.
Gene therapy pipeline for neurology indications dominated by viral vectors
Of the 38 pipeline products that are currently in development stages, AAV-based delivery platforms account for 45% of these products.
Soliris – Treatment for PNH, aHUS, gMG, and NMOSD
Soliris (eculizumab) is a drug indicated for the treatment of paroxysmal nocturnal haemoglobinuria (PNH), atypical haemolytic uremic syndrome (aHUS), generalised myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD).
Verzenio (abemaciclib) for the Treatment of Metastatic Breast Cancer
Verzenio (abemaciclib) is a cyclin-dependent kinases (CDK) 4 and 6 inhibitor indicated for the treatment of women with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer.
Lipaglyn (Saroglitazar) for Treating Hypertriglycerdemia in Type II Diabetes
Lipaglyn (Saroglitazar) is a dual peroxisome proliferator-activated receptor (PPAR) agonist indicated for the treatment of hypertriglyceridemia in Type II diabetics.
Olumiant (baricitinib) for the Treatment of Moderate-to-Severe Rheumatoid Arthritis
Olumiant® (baricitinib) is one of the first once-daily oral selective JAK1 and JAK2 inhibitors for the treatment of moderate-to-severe active rheumatoid arthritis (RA).
Cabometyx (cabozantinib) for Treatment of Patients with Advanced Renal Cell Carcinoma
Cabometyx (cabozantinib) is used for the treatment of patients with advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC).